Tiago A Mestre

List of Publications by Year in descending order

104	2,593	186265	233421
papers	citations	28 h-index	45 g-index

110	110	110	3365
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A roadmap for implementation of patientâ€centered digital outcome measures in Parkinson's disease obtained using mobile health technologies. Movement Disorders, 2019, 34, 657-663.	3.9	213
2	Data Analytics from Enrollâ€<scp>HD</scp>, a Global Clinical Research Platform for Huntington's Disease. Movement Disorders Clinical Practice, 2017, 4, 212-224.	1.5	137
3	MDS evidenceâ€based review of treatments for essential tremor. Movement Disorders, 2019, 34, 950-958.	3.9	108
4	Motor and nonmotor heterogeneity of LRRK2â€related and idiopathic Parkinson's disease. Movement Disorders, 2016, 31, 1192-1202.	3.9	102
5	The long-term outcome of orthostatic tremor. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309942.	1.9	100
6	Therapeutic interventions for symptomatic treatment in Huntington's disease. The Cochrane Library, 2009, , CD006456.	2.8	91
7	Canadian guideline for Parkinson disease. Cmaj, 2019, 191, E989-E1004.	2.0	90
8	Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation. Journal of NeuroEngineering and Rehabilitation, 2018, 15, 97.	4.6	71
9	Subthalamic nucleusâ€deep brain stimulation for early motor complications in Parkinson's diseaseâ€”the EARLYSTIM trial: Early is not always better. Movement Disorders, 2014, 29, 1751-1756.	3.9	68
10	Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects. Movement Disorders, 2016, 31, 290-298.	3.9	68
11	Transducer-based evaluation of tremor. Movement Disorders, 2016, 31, 1327-1336.	3.9	64
12	Reproducibility of data-driven Parkinson's disease subtypes for clinical research. Parkinsonism and Related Disorders, 2018, 56, 102-106.	2.2	63
13	Parkinsonâ€™s Disease Subtypes: Critical Appraisal and Recommendations. Journal of Parkinson's Disease, 2021, 11, 395-404.	2.8	56
14	5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders. Expert Opinion on Investigational Drugs, 2013, 22, 411-421.	4.1	53
15	Therapeutic interventions for disease progression in Huntington's disease. The Cochrane Library, 2009, , CD006455.	2.8	52
16	Fifteen Years of Clinical Trials inÂHuntingtonâ€™s Disease: A Very Low ClinicalÂDrug Development Success Rate. Journal of Huntington's Disease, 2017, 6, 157-163.	1.9	50
17	Longâ€term doubleâ€blinded unilateral pedunculopontine area stimulation in Parkinson's disease. Movement Disorders, 2016, 31, 1570-1574.	3.9	47
18	Placebo and nocebo responses in restless legs syndrome. Neurology, 2017, 88, 2216-2224.	1.1	46

#	Article	IF	Citations
19	Another face of placebo: The lessebo effect in Parkinson disease. Neurology, 2014, 82, 1402-1409.	1.1	45
20	Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations. Movement Disorders, 2016, 31, 1466-1478.	3.9	44
21	The Parkinson's disease eâ€diary: Developing a clinical and research tool for the digital age. Movement Disorders, 2019, 34, 676-681.	3.9	43
22	Restless Genital Syndrome in Parkinson Disease. JAMA Neurology, 2014, 71, 1559.	9.0	42
23	Therapy of Parkinson's Disease Subtypes. Neurotherapeutics, 2020, 17, 1366-1377.	4.4	42
24	Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies. Neurotherapeutics, 2020, 17, 1645-1659.	4.4	40
25	Rating scales for cognition in Huntington's disease: Critique and recommendations. Movement Disorders, 2018, 33, 187-195.	3.9	38
26	Gene Expression Differences in Peripheral Blood of Parkinsonâ€™s Disease Patients with Distinct Progression Profiles. PLoS ONE, 2016, 11, e0157852.	2.5	36
27	Development of the Integrated Parkinsonâ€™s Care Network (IPCN): using co-design to plan collaborative care for people with Parkinsonâ€™s disease. Quality of Life Research, 2019, 28, 1355-1364.	3.1	33
28	Technology-Enabled Care: Integrating Multidisciplinary Care in Parkinson's Disease Through Digital Technology. Frontiers in Neurology, 2020, 11, 575975.	2.4	32
29	Diagnosis and treatment of impulse control disorders in patients with movement disorders. Therapeutic Advances in Neurological Disorders, 2013, 6, 175-188.	3.5	29
30	Are genetic and idiopathic forms of Parkinson's disease the same disease?. Journal of Neurochemistry, 2020, 152, 515-522.	3.9	28
31	Measurement Instruments to Assess Functional Mobility in Parkinson's Disease: A Systematic Review. Movement Disorders Clinical Practice, 2020, 7, 129-139.	1.5	28
32	Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations. Movement Disorders Clinical Practice, 2018, 5, 111-117.	1.5	27
33	Moving towards home-based community-centred integrated care in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 78, 21-26.	2.2	27
34	What motivates Parkinsonâ€™s disease patients to enter clinical trials?. Parkinsonism and Related Disorders, 2011, 17, 667-671.	2.2	26
35	What is a clinically important change in the Unified Dyskinesia Rating Scale in Parkinson's disease?. Parkinsonism and Related Disorders, 2015, 21, 1349-1354.	2.2	24
36	Quality of Life in Huntington's Disease: Critique and Recommendations for Measures Assessing Patient Healthâ€Related Quality of Life and Caregiver Quality of Life. Movement Disorders, 2018, 33, 742-749.	3.9	23

#	Article	IF	Citations
37	Uptake of telehealth in Parkinson's disease clinical care and research during the COVID-19 pandemic. Parkinsonism and Related Disorders, 2021, 86, 97-100.	2.2	23
38	Rating Scales and Performanceâ€based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations. Movement Disorders Clinical Practice, 2018, 5, 361-372.	1.5	22
39	Automated assessment of levodopa-induced dyskinesia: Evaluating the responsiveness of video-based features. Parkinsonism and Related Disorders, 2018, 53, 42-45.	2.2	22
40	A novel KCNA1 mutation in a family with episodic ataxia and malignant hyperthermia. Neurogenetics, 2016, 17, 245-249.	1.4	21
41	Placebo and nocebo responses in other movement disorders besides Parkinson's disease: How much do we know?. Movement Disorders, 2018, 33, 1228-1235.	3.9	21
42	Espresso Coffee for the Treatment of Somnolence in Parkinsonâ€™s Disease: Results of n-of-1 Trials. Frontiers in Neurology, 2016, 7, 27.	2.4	19
43	Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics. Current Neurology and Neuroscience Reports, 2017, 17, 18.	4.2	19
44	An <scp>MDS</scp> Evidenceâ€Based Review on Treatments for Huntington's Disease. Movement Disorders, 2022, 37, 25-35.	3.9	19
45	Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2018, 8, 503-510.	2.8	18
46	Nocebo response in Parkinson's disease: A systematic review and meta-analysis. Parkinsonism and Related Disorders, 2019, 65, 13-19.	2.2	18
47	Moving towards Integrated and Personalized Care in Parkinsonâ€™s Disease: A Framework Proposal for Training Parkinson Nurses. Journal of Personalized Medicine, 2021, 11, 623.	2.5	18
48	Bilateral pallidal stimulation for sargoglycan epsilon negative myoclonus. Parkinsonism and Related Disorders, 2014, 20, 915-918.	2.2	17
49	Modelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults: theÂP_REDIGT score. European Journal of Neuroscience, 2017, 45, 175-191.	2.6	17
50	The Disease Modification Conundrum in Parkinsonâ€™s Disease: Failures and Hopes. Frontiers in Aging Neuroscience, 2022, 14, 810860.	3.4	17
51	Can Isolated Enlarged Virchow-Robin Spaces Influence the Clinical Manifestations of Parkinson's Disease?. Movement Disorders Clinical Practice, 2014, 1, 67-69.	1.5	14
52	Recent advances in the therapeutic development for Huntington disease. Parkinsonism and Related Disorders, 2019, 59, 125-130.	2.2	13
53	Pilot Evaluation of a Pragmatic Network for Integrated Care and Selfâ€Management in Parkinson's Disease. Movement Disorders, 2021, 36, 398-406.	3.9	13
54	Remote Evaluation of Parkinson's Disease Using a Conventional Webcam and Artificial Intelligence. Frontiers in Neurology, 2021, 12, 742654.	2.4	13

#	Article	IF	Citations
55	Clustering of motor and nonmotor traits in leucineâ€rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study. Movement Disorders, 2018, 33, 960-965.	3.9	12
56	Drooling rating scales in Parkinson's disease: A systematic review. Parkinsonism and Related Disorders, 2021, 91, 173-180.	2.2	12
57	Co-designing a digital companion with people living with Parkinson's to support self-care in a personalized way: The eCARE-PD Study. Digital Health, 2022, 8, 205520762210816.	1.8	11
58	Small and Large Magnetic Resonance Imagingâ€"Visible Perivascular Spaces in the Basal Ganglia of Parkinson's Disease Patients. Movement Disorders, 2022, 37, 1304-1309.	3.9	11
59	Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers. Journal of Parkinson's Disease, 2018, 8, 131-139.	2.8	10
60	Glycopyrrolate Improves Disability From Sialorrhea in Parkinson's Disease: A <scp>12â€Week</scp> Controlled Trial. Movement Disorders, 2020, 35, 2319-2323.	3.9	10
61	Vitamins and Infusion of Levodopa-Carbidopa Intestinal Gel. Canadian Journal of Neurological Sciences, 2022, 49, 19-28.	0.5	8
62	Strong nocebo effect in amyotrophic lateral sclerosis trials might mask conclusions. Lancet Neurology, The, 2018, 17, 842.	10.2	7
63	Nocebo and lessebo effects. International Review of Neurobiology, 2020, 153, 121-146.	2.0	7
64	The Integrated Parkinsonâ€™s disease Care Network (IPCN): Qualitative evaluation of a new approach to care for Parkinsonâ€™s disease. Patient Education and Counseling, 2021, 104, 136-142.	2.2	7
65	Epidemiology and economic burden of Huntingtonâ€™s disease: a Canadian provincial public health system perspective. Journal of Medical Economics, 2022, 25, 212-219.	2.1	7
66	Current Use of Domperidone and Co-prescribing of Medications that Increase Its Arrhythmogenic Potential Among Older Adults: A Population-Based Cohort Study in Ontario, Canada. Drugs and Aging, 2014, 31, 805-813.	2.7	6
67	Placebos in clinical trials: unravelling a complex phenomenon. Lancet Neurology, The, 2017, 16, 28-29.	10.2	6
68	Reluctance to start medication for Parkinson's disease: A mutual misunderstanding by patients and physicians. Parkinsonism and Related Disorders, 2014, 20, 608-612.	2.2	5
69	Impact of New Technologies in a Stroke Presentation: A Case of Dystextia and Dystypia. Canadian Journal of Neurological Sciences, 2017, 44, 458-460.	0.5	5
70	The Role of Architecture and Design in the Management of Parkinsonâ€™s Disease: A Systematic Review. Journal of Parkinson's Disease, 2020, 10, 1301-1314.	2.8	5
71	Toward <scp>eâ€Scales</scp>: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales. Movement Disorders Clinical Practice, 2021, 8, 208-214.	1.5	5
72	Designing socially acceptable mHealth technologies for Parkinson's disease self-management. Finnish Journal of EHealth and EWelfare, 2020, 12, 163-178.	0.1	5

#	Article	IF	Citations
73	Are placebo pills presented as experimental treatment a true placebo?. Pain, 2017, 158, 535-535.	4.2	4
74	Expectations of Benefit in a Trial of a Candidate Diseaseâ€Modifying Treatment for Parkinson Disease. Movement Disorders, 2021, 36, 1964-1967.	3.9	4
75	Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice. Movement Disorders, 2018, 33, 1195-1203.	3.9	3
76	The dawn of a new era for neurodegenerative disorders: Huntington's disease leading the way. Movement Disorders, 2019, 34, 1301-1302.	3.9	3
77	Synuclein Meeting 2019: where we are and where we need to go. Journal of Neurochemistry, 2019, 150, 462-466.	3.9	3
78	Thyrotoxicosis Resulting in Unilateral Upper Limb Chorea and Ballismus. Canadian Journal of Neurological Sciences, 2021, , 1-2.	0.5	3
79	Validation of biomarkers in Huntington disease to support the development of disease-modifying therapies: A systematic review and critical appraisal scheme. Parkinsonism and Related Disorders, 2021, 93, 89-96.	2.2	3
80	Resolving Missing Data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Implications for Telemedicine. Movement Disorders, 2022, 37, 1749-1755.	3.9	3
81	The Role of Parkinson Nurses for Personalizing Care in Parkinsonâ€™s Disease: A Systematic Review and Meta-Analysis. Journal of Parkinson's Disease, 2022, 12, 1807-1831.	2.8	3
82	The placebo response in Parkinson's disease and other movement disorders. Movement Disorders, 2018, 33, 1193-1194.	3.9	2
83	Patient-centred management of Parkinson's disease. Lancet Neurology, The, 2020, 19, 887-888.	10.2	2
84	Coping Styles in Patients with Parkinsonâ€™s Disease: Consideration in the Co-Designing of Integrated Care Concepts. Journal of Personalized Medicine, 2022, 12, 921.	2.5	2
85	A rare cause of orofacial dyskinesias. Parkinsonism and Related Disorders, 2018, 50, 122-123.	2.2	1
86	Intermittent undulating tongue as an involuntary movement in early amyotrophic lateral sclerosis. Parkinsonism and Related Disorders, 2019, 67, 1-2.	2.2	1
87	F01â€...Development of the huntingtonâ€™s disease integrated staging system (HD-ISS). , 2021, , .		1
88	Evaluation of the Impact of Integrated Care and Self-Management After Deep Brain Stimulation in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 1279-1284.	2.8	1
89	Disease Burden of Huntingtonâ€™s Disease (HD) on People Living with HD and Care Partners in Canada. Journal of Huntington's Disease, 2022, , 1-15.	1.9	1
90	Therapeutic interventions for sleep disorders in Parkinson's disease. The Cochrane Library, 0, , .	2.8	0

#	Article	IF	Citations
91	Therapeutic interventions for daytime somnolence in Parkinson's disease. The Cochrane Library, 2007, , .	2.8	0
92	Emerging targets and other stimulationrelated procedures in the management of Parkinson's disease. , 0, , 216-230.		0
93	A12â€…How does Enroll-HD expedite/facilitate the conduct of clinical trials?. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A4.1-A4.	1.9	0
94	I31â€…Enroll-HD: current status. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A69.2-A70.	1.9	0
95	I30â€…Enroll-HD: a global clinical research platform for huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A69.1-A69.	1.9	0
96	Response to letter by Saenzâ€Farret et al. on â€œRating scales for behavioral symptoms in Huntington's disease: Critique and recommendationsâ€. Movement Disorders, 2017, 32, 482-482.	3.9	0
97	PO104â€…Placebo and nocebo responses in rls: a meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A39.1-A39.	1.9	0
98	Introducing the new â€œMovement Disorders Roundsâ€. Parkinsonism and Related Disorders, 2018, 55, 1.	2.2	0
99	Assessing and managing Parkinson's disease from home: A 21st century vision closer to reality. Movement Disorders, 2018, 33, 1407-1407.	3.9	0
100	Reply to â€œStudying reproducibility of data-driven Parkinson's disease subtypesâ€. Parkinsonism and Related Disorders, 2019, 66, 245-246.	2.2	0
101	An 8-year-old boy with ataxia and abnormal movements. Paediatrics and Child Health, 2019, 24, 297-298.	0.6	0
102	Huntingtonâ€™s Disease and Hypertension: Sorting Out Mixed Messages. Movement Disorders, 2020, 35, 915-917.	3.9	0
103	Return on Investment Analysis for the Integrated Parkinsonâ€™s Care Network: Lesson Learned from a Pilot Study. Journal of Parkinson's Disease, 2021, 11, 1-7.	2.8	0
104	Using Big Data in Movement Disorders: Disease States and Progression in Huntington's Disease. Movement Disorders, 2022, 37, 441-443.	3.9	0